MPTP(1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine)로 유도된 Parkinson's Disease 동물 모델을 이용한 향사양위탕의 신경 세포 보호 효과
Neuroprotective Effects of Hyangsayangwi-tang in MPTP-inducedMouse Model of Parkinson's Disease
2
조회
0
다운로드
3
인용
0
참고문헌
키워드
초록
ObjectivesTo evaluate the neuroprotective effects of Hyangsayangwi-tang (HY), a Korean traditional medicinal prescription in a Parkinson's disease mouse model. MethodsFour groups(each of 10 mouse per group) were used in this study. The neuroprotective effect of HY was examined in a Parkinson's disease mouse model. C57BL/6 mouse treated with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP, 30mg/kg/day), intraperitoneal (i.p.) for 5 days. Slow behavioral responses and memory disorder is the major clinical symptoms of PD. In order to investigate the effect of HY on recovery of behavioral deficits and memory, we examined the motor function and memory by using Morris water maze and Forced swimming test. Ischemic mouse brain stained with TTC(2,3,5 triphenyl tetrazolium chloride) in the MPTP-induced Parkinson's disease to find out ischemia and tissue damage in mouse. The convenient, simple, and accurate high-performance liquid chromatography (HPLC) method was established for simultaneous determination of neurotransmitters in MPTP-HY group. To measure the amount of dopamine in mice brain, striatum-substantia nigra, was examined by Bradford assay. Immunohistochemistry was examined in the MPTP-induced Parkinson's disease (PD) mouse to evaluate the neuroprotective effects of Hyangsayangwi-tang on hippocampal lesion, ST and SNpc. Results and ConclusionsHyangsayangwi-tang (HY) prevents MPTP-induced loss of serotonin, hippocampus and TH-ir cell.
Abstract
ObjectivesTo evaluate the neuroprotective effects of Hyangsayangwi-tang (HY), a Korean traditional medicinal prescription in a Parkinson's disease mouse model. MethodsFour groups(each of 10 mouse per group) were used in this study. The neuroprotective effect of HY was examined in a Parkinson's disease mouse model. C57BL/6 mouse treated with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP, 30mg/kg/day), intraperitoneal (i.p.) for 5 days. Slow behavioral responses and memory disorder is the major clinical symptoms of PD. In order to investigate the effect of HY on recovery of behavioral deficits and memory, we examined the motor function and memory by using Morris water maze and Forced swimming test. Ischemic mouse brain stained with TTC(2,3,5 triphenyl tetrazolium chloride) in the MPTP-induced Parkinson's disease to find out ischemia and tissue damage in mouse. The convenient, simple, and accurate high-performance liquid chromatography (HPLC) method was established for simultaneous determination of neurotransmitters in MPTP-HY group. To measure the amount of dopamine in mice brain, striatum-substantia nigra, was examined by Bradford assay. Immunohistochemistry was examined in the MPTP-induced Parkinson's disease (PD) mouse to evaluate the neuroprotective effects of Hyangsayangwi-tang on hippocampal lesion, ST and SNpc. Results and ConclusionsHyangsayangwi-tang (HY) prevents MPTP-induced loss of serotonin, hippocampus and TH-ir cell.
참고문헌 (27)
- Imaki T, "Expression of corticotropin-releasing hormone type 1 receptor in paraventricular nucleus after acute stress", Neuroendocrinology, 73(5), pp.293~301 (2001)
- 배나영, "β-Amyloid로 유도된 신경독성에 대한 熱多寒少湯 加感方의 抗치매효과", 사상체질의학회지, 21(3), pp.138~153 (2009), 사상체질의학회
- Bae NY, "The neuroprotective effect of modified Yeoldahanso-tang via autophagy enhancement in modelsof Parkinson’s disease", Journal of Ethnopharmacology, 134, pp.313~322 (2011)
- Dauer W, "Parkinson’s disease : mechanisms and models", Neuron, 39, pp.889~909 (2003)
- 서진희, "고온 환경에서의 트레드밀 운동이 흰쥐 뇌에서 세로토닌 발현, 신경세포 생성, 그리고 단기 기억력에 미치는 영향", 체육과학연구, 20(4), pp.743~754 (2009), 국민체육진흥공단 부설 한국스포츠개발원
- Smith GW, "Corticotropin releasing factor receptor 1-deficient micedisplay decreased anxiety, impaired stress response, and aberrant neuroendocrine development", Neuron, 20(6), pp.1093~1102 (1998)
- Porsolt RD, "Behavioral despair in rats : A new model sensitive to antidepressant treatments", Eur J Pharmacol, 47, pp.379~391 (1978)
- Porsolt RD, "Animal model of depression", Biomedicine, 30, pp.139~140 (1979)
- Langston, J.W., "Pargyline prevents MPTP-induced parkinsonism in primates", Science, 225(4669), pp.1460~1462 (1984)
- Arai N, "Combined effects of cabergoline and L-dopa on parkinsonism in MPTP-treated cynomolgus monkeys", J Neural Transmission, 103(11), pp.1037~1316 (1996)
- Lau, Y.S., "From drugs of abuse to parkinsonism: The MPTP Mouse Model of Parkinson’s Disease", Methods in Molecular Medicine, 79(1), pp.103~116 (2003)
- Lee JM, "Dongeuisoosebowonsasangbonchokwon", pp.27~278 (2002), Eulyumoonhwasa
- The National College of Oriental Medicine Sasangeuihakclassroom, "Sasangeuihak", pp.260~ (2004), Jipmundang
- Song IB, "Sasangeuihak", pp.343~ (2004), Jipmundang
- Lee JC, "Sinsasangeuihakron Ⅱ", pp.79~83 (2001), Mokkwato
- 정병주, "파킨슨병으로 유발된 진전이 한약 치료를 통하여 호전된 치험 1례", 대한한방내과학회지, 27(4), pp.954~961 (2006), 대한한방내과학회
- Bae NY, "Neuroprotective effect of modified Yeoldahanso-tang via autophagy enhancement on Parkinsonian model", 25(3), pp.208~217 (2013), Dae-jeon National University
- Brian R. Perri, "Metabolic Quantification of Lesion Volume following Experimental Traumatic Brain Injury in the Rat", Journal of Neurotrauma, 14, pp.15~22 (1997)
- Vosselera M., "Area at Risk and Viability after Myocardial Ischemia and Reperfusion Can Be Determined by Contrast-Enhanced Cardiac Magnetic Resonance Imaging", Eur Surg Res, 43, pp.13~23 (2009)
- Kasper, Braunwald, "Harrison`s Principles of Internal medicine", pp.2631~2638 (2006), MIP
- Widdowson, P.S., "No changes in behavior, nigro-striatal system neurochemistry or neuronal cell death following toxic multiple oral paraquat administration to rat", Human and Experomental Toxicology, 15(7), pp.583~591 (1996)
- Ferger, B., "The propective effects of PBN against MPTP toxocity are independent of hydroxyl radical trapping", Phamaco Biochem Behav, 65(3), pp.425~431 (2000)
- Westm B.D., "Amphetamine-induced locomotor activity is reduced in mice following MPTP treatment but not following selegiline", MPTP treatment, 2006, pp.84(1), 158~161
- Sun, L., "Effects of cysteamine on MPTP-induced dopaminergic neurodegeneration in mice", Brain Research, 1335, pp.74~82 (2010)
- Cummings JL, "Depression in Parkinson’s disease：a review", Am J Psychiatry, 149, pp.443~454 (1992)
- Fetoni V, "Affective symptoms in multiple system atropy and Parkinson's disease：response to levodopa therapy", J Neurol Neurosurg Psychiatry, 66, pp.541~544 (1999)
- Burn DJ, "Depression in Parkinson’s disease", Eur J Neurol, 9, pp.44~54 (2002)